China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the start of a Phase III clinical trial for its Category 1 chemical drug ammuxetine at the Shanghai Mental Health Center, a top-tier Class 3A mental hospital.
Drug Profile
Ammuxetine, a small molecule SNR inhibitor discovered by the Chinese Academy of Military Medical Sciences, has completed four Phase I trials in healthy subjects and two Phase II trials in patients with depression. Results showed strong antidepressant effects and a favorable safety profile.
Trial Significance
The Phase III study will further evaluate ammuxetine’s efficacy and safety in a larger patient population. The trial’s location at Shanghai Mental Health Center underscores CSPC’s commitment to rigorous, high-standard clinical research in psychiatry.-Fineline Info & Tech
Leave a Reply